



Beth Israel Deaconess
Medical Center



A teaching hospital of
Harvard Medical School

October 21, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: Sloane Review.rev.docx).

Title: Targeting Remyelination Treatment for Multiple Sclerosis

Author: Nadeem, Lindsay Sklover, Jacob A. Sloane

Name of Journal: *World Journal of Neurology*

ESPS Manuscript NO: 14311

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer #2

1. Recent reports point out the apparent neuronal primary damage in MS, rather than the classical concept of primary demyelination. The authors should mention these thesis and how remyelination could serve as potential therapy. This is discussed in the beginning of this manuscript. We have added this again in conclusion section.

2. On P4,p1,L1-3 the authors mention "several drugs", I think that there are few and most of them in the initial steps for clinical research. We revised this to state "multiple" drugs.

3. It seems to me that the subject of "therapeutic antibodies" (P4,p2) should be placed under a separate subheadings from pharmacological substances. We respectfully feel this change would confer no meaningful improvement to the manuscript so we left things as they are.

4. It should receive conceptual consideration that remyelination does not signify functional recovery. We have added a sentence stating this

3 References and typesetting were corrected



Beth Israel Deaconess
Medical Center



A teaching hospital of
Harvard Medical School

Thank you again for publishing our manuscript in the *World Journal of Neurology*.

Sincerely yours,

hD

Director, MS Center
Beth Israel Deaconess Medical Center
Dept. Neurology, Ks212
330 Brookline Ave
Boston, MA 02115
Fax: 617-667-1869
E-mail: jsloane@bidmc.harvard.edu